RxDoctor Payments Data

Lisa Baddi, DO

Hematology & Oncology · Chicago, ILNPI 1780683250

Payments from drug & device makers

$18,909in general payments, 2019–2025

Across 524 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stemline Therapeutics Inc.$5K
  • AstraZeneca$3K
  • Novartis$2K
  • Gilead$847
  • Merck$577
  • Pfizer$573
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$7,38539%
  • Food & beverage$10,86057%
  • Education$6634%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stemline Therapeutics Inc.3$4,965
AstraZeneca23$2,882
Novartis109$1,815
Gilead(2 entities)36$847
Merck30$577
Pfizer25$573
Genentech USA, Inc.24$540
AbbVie21$464
Bristol Myers Squibb17$445
Seagen Inc.14$381
E.r. Squibb & Sons, L.L.C.18$373
Incyte Corporation10$316
Amgen9$293
Pharmacyclics LLC, An Abbvie Company10$263
Puma Biotechnology, Inc.8$252
Boston Scientific6$241
GSK9$238
Johnson & Johnson(2 entities)10$235
Astellas Pharma US Inc8$195
Takeda Pharmaceuticals U.S.A., Inc.7$194
Eisai Inc.9$184
Servier Pharmaceuticals LLC8$174
Daiichi Sankyo Inc.8$168
Sanofi9$158
Sobi, Inc3$143
Pharmacosmos Therapeutics Inc.5$113
Karyopharm Therapeutics Inc.5$106
Inari Medical, Inc.1$104
EMD Serono, Inc.6$102
Bayer5$96
G1 Therapeutics, Inc.4$79
Jazz Pharmaceuticals Inc.3$64
Agios Pharmaceuticals, Inc.3$64
Taiho Oncology, Inc.3$59
Array Biopharma Inc2$58
Boehringer Ingelheim2$57
Amneal Pharmaceuticals LLC3$57
Blueprint Medicines Corporation2$55
Kyowa Kirin, Inc.3$54
Mirati Therapeutics, Inc.2$50
Menarini Silicon Biosystems, Inc.1$48
Deciphera Pharmaceuticals Inc.2$48
AVEO Pharmaceuticals, Inc.3$45
Tempus AI, Inc2$45
AMAG Pharmaceuticals, Inc.3$42
Dendreon Pharmaceuticals LLC2$41
Springworks Therapeutics, Inc.1$40
Verity Pharmaceuticals Inc.2$38
Tersera Therapeutics LLC1$36
Pharmaessentia USA Corporation1$33
Biocon Biologics Inc2$32
Sumitomo Pharma America, Inc.1$28
Legend Biotech USA Inc.1$28
GE HealthCare1$27
Tolmar Pharmaceuticals, Inc.1$25
Myriad Genetic Laboratories, Inc.1$25
Verastem, Inc.1$24
Rigel Pharmaceuticals, Inc.1$24
Morphosys, US Inc.1$24
Caris MPI, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,909 in reported general payments places this provider in the 55th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,371,778
Medicare patients
419
Services billed
125,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib23$334,526
IbrancePalbociclib12$199,968
RevlimidLenalidomide13$43,858
EliquisApixaban17$10,953
Anastrozole258$5,124
Letrozole81$1,345
Hydroxyurea23$1,277
Fentanyl11$1,101
Tamoxifen Citrate43$889
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$773
Potassium Chloride31$256
Ondansetron OdtOndansetron16$246
Alendronate Sodium27$223
Dexamethasone25$214
Prochlorperazine Maleate19$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$573$210,92029 claims
Bristol Myers SquibbRevlimid$445$43,85813 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$57$16832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →